Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | SDHA | P31040 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CALML3 | P27482 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291752 | 1.00 | MAOA (0.52) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6291299 | 0.94 | MAOA (0.54) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6040320 | 0.92 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14336400 | 0.91 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6208968 | 0.91 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14334857 | 0.90 | MAOA (0.53) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6292470 | 0.89 | MAOA (0.55) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6291313 | 0.88 | TMEM97 (0.61) | — | |
| SCHEMBL6291694 | 0.87 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6291691 | 0.87 | MAOA (0.48) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | JOHNSON PAUL D (US) | 2004-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186293-A1 | Oxazolidinones having a benzannulated 6- or 7-membered heterocycle | OXA1L, CDK16, MT-ND6 | MAOA 810/4885MAOB 754/4885PTGS1 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.